Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2019
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms TRIUMPH study
- 27 Dec 2018 Planned number of patients changed from 36 to 50.
- 21 Dec 2017 Status changed from not yet recruiting to recruiting.
- 03 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 16 Nov 2017.